Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Castrate-resistant prostate cancer (CRPC) is challenging to treat with the androgen receptor (AR), the main target and key focus of resistance. Understanding the mechanisms of AR interaction with co-regulators will identify new therapeutic targets to overcome AR resistance mechanisms. We previously identified the serum response factor (SRF) as a lead target in an in vitro model of CRPC and showed that SRF expression in tissues of CRPC patients was associated with shorter survival. Here, we tested SRF inhibition in vitro and in vivo to assess SRF as a potential target in CRPC. Inhibition of SRF with the small-molecule inhibitor CCG1423 resulted in enhanced response to enzalutamide in vitro and reduced tumour volume of LuCaP 35CR, a CRPC patient-derived xenograft model. Nuclear localisation of AR post-CCG1423 was significantly decreased and was associated with decreased α-tubulin acetylation in vitro and decreased prostate specific antigen (PSA) levels in vivo. SRF immunoreactivity was tested in metastatic tissues from CRPC patients to investigate its role in enzalutamide response. Kaplan–Meier curves showed that high SRF expression was associated with shorter response to enzalutamide. Our study supports the use of SRF inhibitors to improve response to enzalutamide.
Funding Information
  • Science Foundation Ireland (18/SIRG/5510, OPTi-PREDICT grant #15/IA/3104, Strategic Research Programme Precision Oncology Ireland grant #18/SPP/3522)
  • Irish Cancer Society (#CRF12PRE)
  • Department of Defense Prostate Cancer Biorepository Network (PCBN) (W81XWH-14-2-0183)
  • Pacific Northwest Prostate Cancer SPORE (P50CA97186)
  • PO1 NIH grant (PO1 CA163227)

This publication has 30 references indexed in Scilit: